News & Media

Recent updates from Arcutis.

September 20, 2022 Featured

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

July 29, 2022 Featured

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

February 8, 2023

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

February 3, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 14, 2023

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

January 5, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2022

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

December 12, 2022

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

December 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 5, 2022

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

December 1, 2022

MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

November 28, 2022

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

November 21, 2022

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

November 17, 2022

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download